Citadel Advisors

Citadel Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Citadel Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-102,700	Closed	-$21K	–	14097
2020 Q4	$21K	Buy	+102,700	New	+$219K	﹤0.01%	10777

Other funds holding BMY.RT

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Citadel Advisors's BMY.RT Position: Q1 2021 in Review

Citadel Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,952,625 shares.

Citadel Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $85.7M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Citadel Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Citadel Advisors sold 10,952,625 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
Citadel Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Citadel Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $85.7M in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.